Close menu

SURE

Sunderland Repository records the research produced by the University of Sunderland including practice-based research and theses.

Cell Cycle Phase-Specific Drug Resistance as an Escape Mechanism of Melanoma Cells

Beaumont, Kimberley A., Hill, David, Daignault, Sheena M., Lui, Goldie Y.L., Sharp, Danae M., Gabrielli, Brian, Weninger, Wolfgang and Haass, Nikolas K. (2016) Cell Cycle Phase-Specific Drug Resistance as an Escape Mechanism of Melanoma Cells. Journal of Investigative Dermatology, 136 (7). pp. 1479-1489. ISSN 0022-202X

Item Type: Article

Abstract

The tumor microenvironment is characterized by cancer cell subpopulations with heterogeneous cell cycle profiles. For example, hypoxic tumor zones contain clusters of cancer cells that arrest in G(1) phase. It is conceivable that neoplastic cells exhibit differential drug sensitivity based on their residence in specific cell cycle phases. In this study, we used two-dimensional and organotypic melanoma culture models in combination with fluorescent cell cycle indicators to investigate the effects of cell cycle phases on clinically used drugs. We demonstrate that G(1)-arrested melanoma cells, irrespective of the underlying cause mediating G(1) arrest, are resistant to apoptosis induced by the proteasome inhibitor bortezomib or the alkylating agent temozolomide. In contrast, G(1)-arrested cells were more sensitive to mitogen-activated protein kinase pathway inhibitor-induced cell death. Of clinical relevance, pretreatment of melanoma cells with a mitogen-activated protein kinase pathway inhibitor, which induced G(1) arrest, resulted in resistance to temozolomide or bortezomib. On the other hand, pretreatment with temozolomide, which induced G(2) arrest, did not result in resistance to mitogen-activated protein kinase pathway inhibitors. In summary, we established a model to study the effects of the cell cycle on drug sensitivity. Cell cycle phase-specific drug resistance is an escape mechanism of melanoma cells that has implications on the choice and timing of drug combination therapies.

Full text not available from this repository.

More Information

Depositing User: Michelle Marshall

Identifiers

Item ID: 11399
Identification Number: https://doi.org/10.1016/j.jid.2016.02.805
ISSN: 0022-202X
URI: http://sure.sunderland.ac.uk/id/eprint/11399
Official URL: http://dx.doi.org/10.1016/j.jid.2016.02.805

Users with ORCIDS

Catalogue record

Date Deposited: 18 Dec 2019 14:04
Last Modified: 09 Feb 2021 18:26

Contributors

Author: Kimberley A. Beaumont
Author: David Hill
Author: Sheena M. Daignault
Author: Goldie Y.L. Lui
Author: Danae M. Sharp
Author: Brian Gabrielli
Author: Wolfgang Weninger
Author: Nikolas K. Haass

University Divisions

Faculty of Health Sciences and Wellbeing
Faculty of Health Sciences and Wellbeing > School of Nursing and Health Sciences

Actions (login required)

View Item View Item